Trial
NCT06901349
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Obesity
Intervention
Bimagrumab
Why stopped
Study terminated for strategic business reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-24